Consenso uruguayo de manejo del infarto agudo de ... - SciELO

More documents

Recommendations

Info

Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-83. 158. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-302. 159. Kuck KH, Capatto R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg(CASH). Circulation 2000; 102: 748-54. 160. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21(24): 2071-8. 161. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-40. 162. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346(12): 877- 83. Epub 2002 Mar 19. 163. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999; 341(25): 1882-90. 164. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004; 44: 2166-72. 165. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation 2004; 109: 2685-91. 166. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverterdefibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-8. 167. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004; 109: 1082-4. 168. Gillis AM. Prophylactic Implantable Cardioverter-Defibrillator after Myocardial Infartion: Not for Everyone. N Engl J Med 2004; 351: 2540-2.
169. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37. 170. Gehi A, Haas D, Fuster V. Primary Prophylaxis with the Implantable Defibrillator: The Need for Improved Risk Stratification. JAMA 2005; 294(8): 958-60. 171. McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med 2005; 352: 222-4. 172. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De- Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50. 173. Buxton AE, Moss AJ. Controversies in Cardiovascular Medicine: Should every one with an ejection fraction less or equal to 30%receive an implantable cardioverter defibrillator?. Circulation 2005; 111: 2537-49. 174. Hohnloser SH, Gersh BJ. Changing late prognosis of acute myocardial infarction. Impact on management of ventricular arrhythmias in the era of reperfusion and the implantable cardioverter-defibrillator. Circulation 2003; 107: 941-6. 175. Domanski MJ, Sakseena S, Epstein AE, Hallstrom AP, Brodsky MA, Kim S, et al. Relative effectiveness of the implantable cardioverterdefibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias: AVID Investigators, Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999; 34: 1090-5. 176. La-Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction: ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-84. 177. Zuanetti G, Neilson JM, Latini R, Santoro E, Maggioni AP, Ewing DJ. Prognostic significance of heart rate variability in postmyocardial infarction patients in the fibrinolytic era, The GISSI-2 results: Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Circulation 1996; 94: 432-6. 178. Savard P, Rouleau JL, Ferguson J, Poitras N, Morel P, Davies RF, et al. Risk stratification after myocardial infarction using signalaveraged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 1997; 96: 202-13. 179. Gomes JA, Winters SL, Martinson M, Machac J, Stewart D, Targonski A. The prognostic significance of quantitative signal-averaged variables relative to clinical variables, site of myocardial infarction, ejection fraction and ventricular premature beats: a prospective study. J Am Coll Cardiol 1989; 13(2): 377-84. 180. Maggioni AP, Zuanetti G, Franzosi MG, Rovelli F, Santoro E,
Page 1 and 2:
CONSENSO REV URUG CARDIOL 2006; 21
Page 3 and 4:
Gabriel Vanerio GRUPO 9. MANEJO AL
Page 5 and 6:
3. CONSIDERACIONES PREVIAS La magni
Page 7 and 8:
Se resalta, además, que sería má
Page 9 and 10:
ealizada muy tempranamente, puede n
Page 11 and 12:
El efecto beneficioso de los nitrat
Page 13 and 14:
Valsartan y Candesartan han demostr
Page 15 and 16:
segmento ST como signo isquémico,
Page 17 and 18:
al menos 36 angioplastias primarias
Page 19 and 20: la heparina no era necesaria como c
Page 21 and 22: En virtud de estas consideraciones
Page 23 and 24: los pacientes de alto riesgo (86-88
Page 25 and 26: primeras 48 horas se individualizar
Page 27 and 28: insuficiencia cardíaca o diabetes
Page 29 and 30: elementos de hipoperfusión perifé
Page 31 and 32: g. luego de IAM con significativa d
Page 33 and 34: El cateterismo derecho puede aporta
Page 35 and 36: . en pacientes con monitorización
Page 37 and 38: a. Betabloqueantes vía oral o intr
Page 39 and 40: . Bloqueo auriculoventricular trans
Page 41 and 42: Si el paciente no tiene ninguno de
Page 43 and 44: tratamiento adecuado. La angioplast
Page 45 and 46: no sostenida, etcétera. El estudio
Page 47 and 48: pacientes indefinidamente* Betabloq
Page 49 and 50: incrementar la actividad de la vida
Page 51 and 52: fumadores desde la etapa de hospita
Page 53 and 54: catalogarse el valor de LDL como ba
Page 55 and 56: las posibilidades de infarto y acci
Page 57 and 58: Infarction: A Meta-analysis. JAMA 2
Page 59 and 60: Coll Cardiol 1998; 32: 634-40. 38.
Page 61 and 62: 61. Pfeffer MA, McMurray JJ, Velazq
Page 63 and 64: facilities: a safety and feasibilit
Page 65 and 66: with the low-molecular-weight hepar
Page 67 and 68: evaluation and management of chroni
Page 69: 147. Teo KK, Yusuf S, Furberg CD. E
Page 73 and 74: 192. Fiore MC, Smith SS, Jorenby DE
Page 75: Hlatky M, et al. Cardiovascular dis
show all

Consenso uruguayo de manejo del infarto agudo de ... - SciELO

Create successful ePaper yourself

Delete template?

Save as template?